Nanobiosystems for Antimicrobial Drug-Resistant Infections

The worldwide increased bacterial resistance toward antimicrobial therapeutics has led investigators to search for new therapeutic options. Some of the options currently exploited to treat drug-resistant infections include drug-associated nanosystems. Additionally, the use of bacteriophages alone or...

Full description

Bibliographic Details
Main Authors: Foteini Gkartziou, Nikolaos Giormezis, Iris Spiliopoulou, Sophia G. Antimisiaris
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Nanomaterials
Subjects:
Online Access:https://www.mdpi.com/2079-4991/11/5/1075
id doaj-5e91c20afd544bd78a001185cad78e35
record_format Article
spelling doaj-5e91c20afd544bd78a001185cad78e352021-04-22T23:01:26ZengMDPI AGNanomaterials2079-49912021-04-01111075107510.3390/nano11051075Nanobiosystems for Antimicrobial Drug-Resistant InfectionsFoteini Gkartziou0Nikolaos Giormezis1Iris Spiliopoulou2Sophia G. Antimisiaris3Institute of Chemical Engineering, FORTH/ICES, Platani, 26504 Patras, GreeceNational Reference Centre for Staphylococci, School of Medicine, University of Patras, 26504 Patras, GreeceNational Reference Centre for Staphylococci, School of Medicine, University of Patras, 26504 Patras, GreeceInstitute of Chemical Engineering, FORTH/ICES, Platani, 26504 Patras, GreeceThe worldwide increased bacterial resistance toward antimicrobial therapeutics has led investigators to search for new therapeutic options. Some of the options currently exploited to treat drug-resistant infections include drug-associated nanosystems. Additionally, the use of bacteriophages alone or in combination with drugs has been recently revisited; some studies utilizing nanosystems for bacteriophage delivery have been already reported. In this review article, we focus on nine pathogens that are the leading antimicrobial drug-resistant organisms, causing difficult-to-treat infections. For each organism, the bacteriophages and nanosystems developed or used in the last 20 years as potential treatments of pathogen-related infections are discussed. Summarizing conclusions and future perspectives related with the potential of such nano-antimicrobials for the treatment of persistent infections are finally highlighted.https://www.mdpi.com/2079-4991/11/5/1075antimicrobial resistanceMRSAnanoparticleliposomesdrugbacteriophage
collection DOAJ
language English
format Article
sources DOAJ
author Foteini Gkartziou
Nikolaos Giormezis
Iris Spiliopoulou
Sophia G. Antimisiaris
spellingShingle Foteini Gkartziou
Nikolaos Giormezis
Iris Spiliopoulou
Sophia G. Antimisiaris
Nanobiosystems for Antimicrobial Drug-Resistant Infections
Nanomaterials
antimicrobial resistance
MRSA
nanoparticle
liposomes
drug
bacteriophage
author_facet Foteini Gkartziou
Nikolaos Giormezis
Iris Spiliopoulou
Sophia G. Antimisiaris
author_sort Foteini Gkartziou
title Nanobiosystems for Antimicrobial Drug-Resistant Infections
title_short Nanobiosystems for Antimicrobial Drug-Resistant Infections
title_full Nanobiosystems for Antimicrobial Drug-Resistant Infections
title_fullStr Nanobiosystems for Antimicrobial Drug-Resistant Infections
title_full_unstemmed Nanobiosystems for Antimicrobial Drug-Resistant Infections
title_sort nanobiosystems for antimicrobial drug-resistant infections
publisher MDPI AG
series Nanomaterials
issn 2079-4991
publishDate 2021-04-01
description The worldwide increased bacterial resistance toward antimicrobial therapeutics has led investigators to search for new therapeutic options. Some of the options currently exploited to treat drug-resistant infections include drug-associated nanosystems. Additionally, the use of bacteriophages alone or in combination with drugs has been recently revisited; some studies utilizing nanosystems for bacteriophage delivery have been already reported. In this review article, we focus on nine pathogens that are the leading antimicrobial drug-resistant organisms, causing difficult-to-treat infections. For each organism, the bacteriophages and nanosystems developed or used in the last 20 years as potential treatments of pathogen-related infections are discussed. Summarizing conclusions and future perspectives related with the potential of such nano-antimicrobials for the treatment of persistent infections are finally highlighted.
topic antimicrobial resistance
MRSA
nanoparticle
liposomes
drug
bacteriophage
url https://www.mdpi.com/2079-4991/11/5/1075
work_keys_str_mv AT foteinigkartziou nanobiosystemsforantimicrobialdrugresistantinfections
AT nikolaosgiormezis nanobiosystemsforantimicrobialdrugresistantinfections
AT irisspiliopoulou nanobiosystemsforantimicrobialdrugresistantinfections
AT sophiagantimisiaris nanobiosystemsforantimicrobialdrugresistantinfections
_version_ 1721513897948610560